Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive

Tata Main Hospital

Status: Completed

Conditions: Covid19

Treatments: Diagnostic Test: Repeat SARS-CoV-2 IgG antibodies at 45-65 days

Study type: Observational

Funder types: Other

Identifiers

NCT04605952

152473

Details and patient eligibility

About

As a serosurveillance measure asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for COVID-19 IgG antibodies. Of the tested employees who were positive for COVID-19 IgG antibodies the study aimed to find the percentage of cases who retained their COVID-19 IgG antibodies 45-65 days after initially testing positive.

Full description

As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for COVID-19 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020.

The cases who tested positive for COVID-19 IgG antibodies were repeat tested for the presence of COVID-19 IgG at 45-65 days after initially testing positive. This was done with the aim of finding out the percentage of cases retaining their IgG antibodies at 45-65 days of initially testing positive.

Enrollment: 201 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

SARS-CoV-2 IgG antibody positive between 28th June and 15th July 2020

Exclusion criteria

SARS-CoV-2 IgG antibody negative between 28th June and 15th July 2020

Trial design

201 participants in 1 patient group

SARS-CoV-2 IgG antibody positive between 28th June to 15th July 2020

Description:

As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for SARS-CoV-2 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. All those who initially tested SARS-CoV-2 IgG antibody positive were retested at 45-65 days

Treatment:

Diagnostic Test: Repeat SARS-CoV-2 IgG antibodies at 45-65 days